Search clinical trials for: Hormone Receptor Positive

Total 77858 results

Liaoning Tumor Hospital & Institute

Recruiting

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Advanced Breast Cancer

China
Novartis Pharmaceuticals

Recruiting

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5)

Breast Cancer

Germany, Italy, Belgium, Denmark, France, Spain, Finland, Hungary, Ireland, Czechia, Greece, Canada, Portugal, Slovakia, Bulgaria, Poland, Romania
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Ahon Pharmaceutical Co., Ltd.
Affiliated Hospital of Hebei University; The First Hospital of Jilin University and other collaborators

Recruiting

Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin

Breast Neoplasms

China
Guangdong Women and Children Hospital

Not yet recruiting

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Breast Cancer
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC (CAPACITY)

Hormone Receptor Positive Advanced Breast Cancer

China
First Affiliated Hospital of Zhejiang University

Recruiting

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

China
Royal Marsden NHS Foundation Trust
Pfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaborators

Recruiting

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER)

HER2-negative Breast Cancer | ER+ Breast Cancer

United Kingdom, France
Washington University School of Medicine
Biovica

Recruiting

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Breast Cancer | Cancer of the Breast

United States
Novartis Pharmaceuticals

Recruiting

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

Spain, Italy, Austria
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo, Inc.

Recruiting

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST)

Metastatic Breast Cancer

France
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
Sociedad Española de Medicina Nuclear e Imagen...

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177 (SEPTRALU)

Digestive System Diseases | Neoplasms | Neoplasms by Histologic Type | Neoplasms by Site | Endocrine System Diseases | Stomach Neoplasms | Gastrointestinal Neoplasms | Digestive System Neoplasms | Neoplasms, Germ Cell and Embryonal | Endocrine Gland Neoplasms | Neuroectodermal Tumors | Neoplasms, Nerve Tissue | Intestinal Diseases and other conditions

Spain
St Vincent's Hospital, Sydney

Recruiting

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer (4CAST)

Triple Negative Breast Cancer

Australia
Yonsei University

Not yet recruiting

Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')

Breast Cancer

Korea, Republic of
Exelixis

Recruiting

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors

United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

Hormone Receptor-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Breast Cancer | Hormone-receptor Positive Breast Cancer

China
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
SOLTI Breast Cancer Research Group
Novartis

Recruiting

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors (ACROPOLI)

Melanoma | Sarcoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Uterine Carcinosarcoma | Mesothelioma | Cholangiocarcinoma | Lung Adenocarcinoma | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal... and other conditions

Spain
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

HR-positive, HER2-negative Advanced Breast Cancer

China
Marina N Sharifi
Novartis; University of Wisconsin, Madison

Recruiting

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer

Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | PIK3CA Mutant Metastatic Breast Cancer

United States
Theratechnologies
PPD; Syneos Health; Windtree Therapeutics; Innovaderm Research Inc.; Altasciences...

Recruiting

TH1902 in Patients With Advanced Solid Tumors

Solid Tumor | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Small-cell Lung Cancer | Thyroid Cancer | Cutaneous Melanoma | TNBC - Triple-Negative Breast Cancer | Hormone Receptor-positive Breast Cancer | SORT1+ Cancers

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Clinical Stage... and other conditions

United States
SCRI Development Innovations, LLC
Daiichi Sankyo, Inc.

Recruiting

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Metastatic Breast Cancer | Locally Advanced Breast Cancer

United States
Instituto do Cancer do Estado de São Paulo

Recruiting

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer (LARA)

Breast Cancer

Brazil
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer

Breast Cancer

China
University of Southern California

Recruiting

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Soft Tissue Sarcoma | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Merkel Cell Carcinoma | Unresectable Melanoma | Unresectable Breast Carcinoma | Bone Sarcoma | Sarcoma,Soft Tissue | Metastatic Breast Carcinoma | Cutaneous Squamous Cell Carcinoma and other conditions

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Breast Cancer | Invasive Carcinoma of the Breast | Node Negative Breast Cancer | Micrometastasis Breast Cancer

United States
Criterium, Inc.

Recruiting

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE)

Breast Cancer

United States
Jonsson Comprehensive Cancer Center
Daiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.S

Recruiting

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Invasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast Cancer

United States
Shengjing Hospital

Recruiting

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Breast Cancer

China
Laura M. Spring, MD
Merck Sharp & Dohme LLC; Translational Breast Cancer Research Consortium; Breast...

Recruiting

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Triple Negative Breast Cancer | Hormone Receptor Positive (HR+), HER2-negative Breast Cancer | Biopsy-proven, Positive Lymph Node(s)

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic Stage II Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma | Hormone Receptor... and other conditions

United States
Second Affiliated Hospital, School of Medicine,...

Not yet recruiting

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer (FAVOR)

HER2-positive Breast Cancer

China
Sun Yat-sen University

Recruiting

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Breast Cancer | Brain Metastases

China
Consorzio Oncotech

Recruiting

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Hormone Receptor Positive Breast Carcinoma | Metastatic Breast Carcinoma

United States
Gencurix, Inc.

Recruiting

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Early Hormone Receptor-positive Breast Cancer

Korea, Republic of
Medical College of Wisconsin

Recruiting

Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer

Invasive Breast Cancer

United States
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC; Seagen Inc.

Recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Locally Advanced or Metastatic Malignant Solid Tumors

United States, Japan, Canada
Fuzhou General Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor

China
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Recruiting

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. (DOMINO-START)

Pituitary Adenoma | Medulloblastoma | Meningioma | Esthesioneuroblastoma | Paraganglioma | CNS Tumors | Hemangioblastoma

United States
Dana-Farber Cancer Institute
Conquer Cancer Foundation

Recruiting

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Breast Neoplasms

China
Memorial Sloan Kettering Cancer Center

Recruiting

Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

Hormone Receptor Positive Metastatic Breast Cancer

United States
Manish Patel
Merck Sharp & Dohme LLC

Recruiting

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Salivary Gland Carcinoma

United States
Peking Union Medical College Hospital

Not yet recruiting

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Pyrotinib)

Breast Diseases | Metastatic Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Breast Cancer Female | Hormone Receptor Positive Tumor
St Vincent's Hospital

Recruiting

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro)

Hormone Receptor Positive Tumor | Early-stage Breast Cancer

Australia

Search clinical trials for: Hormone Receptor Positive

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations